Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice - PubMed
5 hours ago
- #CRS and ICANS risk factors
- #tarlatamab
- #small cell lung cancer
- Tarlatamab is the preferred second-line therapy for extensive stage small cell lung cancer (ES-SCLC).
- CRS risk factors include high disease burden, hepatic disease, and baseline oxygen use.
- ICANS risk factors include high disease burden and a history of CNS disease.
- Unstable brain metastasis in patients with CNS disease increases ICANS risk.
- Efficacy outcomes: ORR 33.7%, PFS 3.58 months, median OS 8.48 months.
- CNS-specific ORR was 33.3%, including four complete responses without radiation.
- Tarlatamab shows manageable toxicity and clinically relevant efficacy in high-risk populations.